Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Show more

Location: 3060 Pegasus Park Drive, Dallas, TX, 75247, United States | Website: https://www.fortebiorx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

153.3M

52 Wk Range

$4.11 - $28.68

Previous Close

$12.33

Open

$12.28

Volume

101,305

Day Range

$11.71 - $12.48

Enterprise Value

47.15M

Cash

106.1M

Avg Qtr Burn

-9.64M

Insider Ownership

4.96%

Institutional Own.

85.47%

Qtr Updated

06/30/25